General Information of Drug (ID: DM8CGUV)

Drug Name
MCLA-145 Drug Info
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM8CGUV

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Co-stimulatory molecule 4-1BB (CD137) TTPW9LJ TNR9_HUMAN Agonist [2]
Programmed cell death 1 ligand 1 (PD-L1) TT8ZLTI PD1L1_HUMAN Agonist [3]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Lymphoma
ICD Disease Classification 2A80-2A86
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death 1 ligand 1 (PD-L1) DTT CD274 4.38E-07 0.37 2.1
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03922204) A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Merus.
3 Clinical pipeline report, company report or official report of Merus.